Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
361 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Tuberculosis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Tuberculosis - Pipeline Review, H2 2015', provides an overview of the Tuberculosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Tuberculosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tuberculosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Tuberculosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 Tuberculosis Overview 7 Therapeutics Development 8 Tuberculosis - Therapeutics under Development by Companies 10 Tuberculosis - Therapeutics under Investigation by Universities/Institutes 16 Tuberculosis - Pipeline Products Glance 21 Tuberculosis - Products under Development by Companies 25 Tuberculosis - Products under Investigation by Universities/Institutes 32 Tuberculosis - Companies Involved in Therapeutics Development 37 Tuberculosis - Therapeutics Assessment 97 Drug Profiles 108 Tuberculosis - Recent Pipeline Updates 303 Tuberculosis - Dormant Projects 322 Tuberculosis - Discontinued Products 330 Tuberculosis - Product Development Milestones 331 Appendix 342
List of Tables
Number of Products under Development for Tuberculosis, H2 2015 26 Number of Products under Development for Tuberculosis - Comparative Analysis, H2 2015 27 Number of Products under Development by Companies, H2 2015 29 Number of Products under Development by Companies, H2 2015 (Contd..1) 30 Number of Products under Development by Companies, H2 2015 (Contd..2) 31 Number of Products under Development by Companies, H2 2015 (Contd..3) 32 Number of Products under Development by Companies, H2 2015 (Contd..4) 33 Number of Products under Investigation by Universities/Institutes, H2 2015 35 Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 36 Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 37 Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..3) 38 Comparative Analysis by Late Stage Development, H2 2015 39 Comparative Analysis by Clinical Stage Development, H2 2015 40 Comparative Analysis by Early Stage Development, H2 2015 41 Comparative Analysis by Unknown Stage Development, H2 2015 42 Products under Development by Companies, H2 2015 43 Products under Development by Companies, H2 2015 (Contd..1) 44 Products under Development by Companies, H2 2015 (Contd..2) 45 Products under Development by Companies, H2 2015 (Contd..3) 46 Products under Development by Companies, H2 2015 (Contd..4) 47 Products under Development by Companies, H2 2015 (Contd..5) 48 Products under Development by Companies, H2 2015 (Contd..6) 49 Products under Investigation by Universities/Institutes, H2 2015 50 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 51 Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 52 Products under Investigation by Universities/Institutes, H2 2015 (Contd..3) 53 Products under Investigation by Universities/Institutes, H2 2015 (Contd..4) 54 Tuberculosis - Pipeline by Abera Bioscience AB, H2 2015 55 Tuberculosis - Pipeline by Achillion Pharmaceuticals, Inc., H2 2015 56 Tuberculosis - Pipeline by Akthelia Pharmaceuticals Limited, H2 2015 57 Tuberculosis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2015 58 Tuberculosis - Pipeline by Archivel Farma S.L., H2 2015 59 Tuberculosis - Pipeline by AstraZeneca Plc, H2 2015 60 Tuberculosis - Pipeline by BioDiem Ltd, H2 2015 61 Tuberculosis - Pipeline by BioLingus AG, H2 2015 62 Tuberculosis - Pipeline by Biomar Microbial Technologies, H2 2015 63 Tuberculosis - Pipeline by Bioversys AG, H2 2015 64 Tuberculosis - Pipeline by Celgene Corporation, H2 2015 65 Tuberculosis - Pipeline by Cellceutix Corporation, H2 2015 66 Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2015 67 Tuberculosis - Pipeline by CureVac GmbH, H2 2015 68 Tuberculosis - Pipeline by Dafra Pharma International Ltd., H2 2015 69 Tuberculosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 70 Tuberculosis - Pipeline by Eisai Co., Ltd., H2 2015 71 Tuberculosis - Pipeline by Eli Lilly and Company, H2 2015 72 Tuberculosis - Pipeline by Ensol Biosciences Inc., H2 2015 73 Tuberculosis - Pipeline by EpiVax, Inc., H2 2015 74 Tuberculosis - Pipeline by FIT Biotech Oy, H2 2015 75 Tuberculosis - Pipeline by GangaGen Inc., H2 2015 76 Tuberculosis - Pipeline by GlaxoSmithKline Plc, H2 2015 77 Tuberculosis - Pipeline by Globeimmune, Inc., H2 2015 78 Tuberculosis - Pipeline by Hsiri Therapeutics, LLC, H2 2015 79 Tuberculosis - Pipeline by Imaxio SA, H2 2015 80 Tuberculosis - Pipeline by Immunitor, Inc., H2 2015 81 Tuberculosis - Pipeline by ImmunoBiology Limited, H2 2015 82 Tuberculosis - Pipeline by Immunovaccine, Inc., H2 2015 83 Tuberculosis - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 84 Tuberculosis - Pipeline by Johnson & Johnson, H2 2015 85 Tuberculosis - Pipeline by Lipotek Pty Ltd., H2 2015 86 Tuberculosis - Pipeline by Microbion Corporation, H2 2015 87 Tuberculosis - Pipeline by Microbiotix, Inc., H2 2015 88 Tuberculosis - Pipeline by NEARMEDIC PLUS, Ltd, H2 2015 89 Tuberculosis - Pipeline by Novartis AG, H2 2015 90 Tuberculosis - Pipeline by Okklo Life Sciences BV, H2 2015 91 Tuberculosis - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H2 2015 92 Tuberculosis - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 93 Tuberculosis - Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H2 2015 94 Tuberculosis - Pipeline by Prokarium Limited, H2 2015 95 Tuberculosis - Pipeline by QureTech Bio AB, H2 2015 96 Tuberculosis - Pipeline by Sanofi, H2 2015 97 Tuberculosis - Pipeline by Sanofi Pasteur SA, H2 2015 98 Tuberculosis - Pipeline by Sarepta Therapeutics, Inc., H2 2015 99 Tuberculosis - Pipeline by SEEK Group, H2 2015 100 Tuberculosis - Pipeline by Sequella, Inc., H2 2015 101 Tuberculosis - Pipeline by Snowdon Inc., H2 2015 102 Tuberculosis - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2015 103 Tuberculosis - Pipeline by Syntrix Biosystems, Inc., H2 2015 104 Tuberculosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 105 Tuberculosis - Pipeline by TetraLogic Pharmaceuticals, H2 2015 106 Tuberculosis - Pipeline by Theravectys SA, H2 2015 107 Tuberculosis - Pipeline by Transgene SA, H2 2015 108 Tuberculosis - Pipeline by TVAX Biomedical, Inc., H2 2015 109 Tuberculosis - Pipeline by Vaccibody AS, H2 2015 110 Tuberculosis - Pipeline by Vakzine Projekt Management GmbH, H2 2015 111 Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd., H2 2015 112 Tuberculosis - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 113 Tuberculosis - Pipeline by Vichem Chemie Research Ltd., H2 2015 114 Assessment by Monotherapy Products, H2 2015 115 Assessment by Combination Products, H2 2015 116 Number of Products by Stage and Target, H2 2015 118 Number of Products by Stage and Mechanism of Action, H2 2015 121 Number of Products by Stage and Route of Administration, H2 2015 123 Number of Products by Stage and Molecule Type, H2 2015 125 Tuberculosis Therapeutics - Recent Pipeline Updates, H2 2015 321 Tuberculosis - Dormant Projects, H2 2015 340 Tuberculosis - Dormant Projects (Contd..1), H2 2015 341 Tuberculosis - Dormant Projects (Contd..2), H2 2015 342 Tuberculosis - Dormant Projects (Contd..3), H2 2015 343 Tuberculosis - Dormant Projects (Contd..4), H2 2015 344 Tuberculosis - Dormant Projects (Contd..5), H2 2015 345 Tuberculosis - Dormant Projects (Contd..6), H2 2015 346 Tuberculosis - Dormant Projects (Contd..7), H2 2015 347 Tuberculosis - Discontinued Products, H2 2015 348
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
